Envestnet Asset Management Inc. Reduces Stock Position in Natera, Inc. (NASDAQ:NTRA)

Envestnet Asset Management Inc. decreased its holdings in Natera, Inc. (NASDAQ:NTRA) by 7.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 162,371 shares of the medical research company’s stock after selling 13,638 shares during the quarter. Envestnet Asset Management Inc. owned approximately 0.12% of Natera worth $22,961,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Fulton Bank N.A. raised its position in shares of Natera by 2.0% in the 1st quarter. Fulton Bank N.A. now owns 3,652 shares of the medical research company’s stock valued at $516,000 after purchasing an additional 71 shares in the last quarter. QRG Capital Management Inc. increased its holdings in shares of Natera by 1.5% in the 1st quarter. QRG Capital Management Inc. now owns 5,417 shares of the medical research company’s stock valued at $766,000 after acquiring an additional 81 shares during the last quarter. Colonial Trust Co SC increased its holdings in shares of Natera by 7.8% in the 4th quarter. Colonial Trust Co SC now owns 1,325 shares of the medical research company’s stock valued at $210,000 after acquiring an additional 96 shares during the last quarter. Silvercrest Asset Management Group LLC grew its stake in Natera by 3.6% during the 4th quarter. Silvercrest Asset Management Group LLC now owns 2,812 shares of the medical research company’s stock worth $445,000 after buying an additional 98 shares during the last quarter. Finally, Utah Retirement Systems grew its stake in Natera by 1.6% during the 4th quarter. Utah Retirement Systems now owns 6,200 shares of the medical research company’s stock worth $981,000 after buying an additional 100 shares during the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Piper Sandler boosted their target price on Natera from $205.00 to $210.00 and gave the stock an “overweight” rating in a research report on Thursday, May 15th. Wall Street Zen lowered Natera from a “hold” rating to a “sell” rating in a research report on Saturday, May 17th. Barclays upped their price target on Natera from $160.00 to $190.00 and gave the company an “overweight” rating in a research report on Friday, May 9th. Finally, UBS Group upped their price target on Natera from $211.00 to $218.00 and gave the company a “buy” rating in a research report on Friday, May 9th. One research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $184.63.

Insiders Place Their Bets

In related news, insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $157.07, for a total value of $471,210.00. Following the sale, the insider owned 133,205 shares of the company’s stock, valued at approximately $20,922,509.35. The trade was a 2.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gail Boxer Marcus sold 4,299 shares of the business’s stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $167.36, for a total value of $719,480.64. Following the transaction, the director directly owned 8,118 shares in the company, valued at approximately $1,358,628.48. This trade represents a 34.62% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 53,272 shares of company stock worth $8,345,368. Corporate insiders own 7.60% of the company’s stock.

Natera Price Performance

NTRA stock opened at $149.85 on Wednesday. The business has a fifty day moving average price of $160.96 and a 200 day moving average price of $158.33. Natera, Inc. has a fifty-two week low of $92.14 and a fifty-two week high of $183.00. The stock has a market capitalization of $20.46 billion, a price-to-earnings ratio of -101.94 and a beta of 1.73.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.09. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The business had revenue of $501.83 million for the quarter, compared to analyst estimates of $446.68 million. During the same period last year, the company earned ($0.56) EPS. The firm’s revenue was up 36.5% on a year-over-year basis. On average, equities analysts expect that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.